New Low-Dose drug schedule shows promise for MDS patients
NCT ID NCT03502668
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tested a low-dose version of the cancer drug ASTX727 in 160 adults with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder. The goal was to find a safer, more effective dosing schedule that improves blood cell counts and reduces the need for blood transfusions. Participants received different doses and schedules to measure safety, side effects, and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Az St-Jan Brugge-Oostende A.V.
Bruges, Belgium
-
BRCR Medical Center Inc.
Plantation, Florida, 33324, United States
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Univeristario y Politecnico La Fe Servicio de Hematologia
Valencia, 46026, Spain
-
Hospital Universitario Vall d Hebron
Barcelona, Spain
-
Indiana University Health Hospital - Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
-
London Regional Cancer Center
London, Ontario, N6A 5W9, Canada
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Moffitt Cancer Center Site#507
Tampa, Florida, 33612, United States
-
Oregon Health and Science University Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)
Bethesda, Maryland, 20817, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universita degli Studi di Firenze
Florence, Italy
-
Universitaetsklinikum Freiburg Site#703
Freiburg im Breisgau, 79106, Germany
-
University of Alberta Hospital - Hematology Research
Edmonton, T6G 2B7, Canada
-
University of Colorado, Anschutz Cancer Pavilion
Aurora, Colorado, 80045, United States
-
University of Kansas Clinical Research Center
Westwood, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Universitätsklinikum Halle
Halle, 06120, Germany
-
Vanderbilt University Medical Center - Hematology-Oncology
Nashville, Tennessee, 37232, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
-
ZNA - Campus Middelheim
Antwerp, Belgium
Conditions
Explore the condition pages connected to this study.